Feed MRNJ
Summary
16 / 100 · Bulios Score
Valuation 50Growth 2Profitability 0Quality 0Debt 42Stability 2
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- Revenue fell by 29% a year over the last 3 years.
- The company made a loss over the last 12 months.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
20212022202320242025
Diluted EPS (USD)
20212022202320242025
Revenue fell by 29% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $66.9K.
Profitability in detailIs it financially healthy?
Cash and short-term investments $8.00
Debt $266.5K
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.